NETwork of Linoleic Acid Supplementation in Cystic Fibrosis
Last updated on July 2021Recruitment
- Recruitment Status
- Enrolling by invitation
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Cystic Fibrosis
- Type
- Interventional
- Phase
- Not Applicable
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: Parallel, double blind, randomizedMasking: Triple (Participant, Care Provider, Investigator)Masking Description: The supplement only differ by colour on capsulae, no labellingPrimary Purpose: Treatment
Participation Requirements
- Age
- Between 5 years and 15 years
- Gender
- Both males and females
Description
Two group of matched children with CF were randomized to two type of oils given 20 g oil and 800 mg DHA daily for one year and anthropometry, pulmonary function, biochemistry, resting energy expenditure, lipid mediators, inflammatory and intestinal markers were studied at start and at 6 months and 1...
Two group of matched children with CF were randomized to two type of oils given 20 g oil and 800 mg DHA daily for one year and anthropometry, pulmonary function, biochemistry, resting energy expenditure, lipid mediators, inflammatory and intestinal markers were studied at start and at 6 months and 1 year. Dietary intake was controlled and life quality recording at start and end of study.
Tracking Information
- NCT #
- NCT04531410
- Collaborators
- European Society of Pediatric Gastroenterology, Hepatology and Nutrition
- Investigators
- Principal Investigator: Jaroslaw Walkowiak, MD,PhD University of Poznan, CF center, Poland Principal Investigator: Carla Colombo, MD,PhD University of Milan, CF center, Italy Principal Investigator: Olav Trond Storrösten, MD, PhD University of Oslo, CF center, Norway
Get Well Soon